[Pharmacokinetics and pharmacodynamics of protirelin (TRH) in man]

Dtsch Med Wochenschr. 1988 Sep 2;113(35):1354-7. doi: 10.1055/s-2008-1067819.
[Article in German]

Abstract

Blood concentrations of thyrotropin-releasing hormone (TRH, Protirelin) were measured by a specific radioimmunoassay in 16 euthyroid subjects after intravenous (200 micrograms), nasal (2 mg) or oral (40 mg) administration of TRH. TRH blood levels peaked 2 min after i.v. administration (13,400 +/- 1,020 fmol/ml), 10 min after nasal (5,000 +/- 1,800 fmol/ml) and 150 min after oral (2,650 +/- 1,080 fmol/ml) administration. The degradation of TRH followed an exponential curve, giving a half-life of 6.5 min. The disappearance rate gave a "half-life" of 22 min in the nasal application group and of 31 min in the oral group. Maximal concentration of stimulated thyrotropin-stimulating hormone (TSH) always occurred 30 min after the peak TRH concentration without any correlation with the TRH concentration time integrals, suggesting that TSH secretion is dependent on a continually rising TRH blood level.

Publication types

  • Clinical Trial
  • Comparative Study
  • Controlled Clinical Trial
  • English Abstract
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Administration, Intranasal
  • Administration, Oral
  • Adult
  • Half-Life
  • Humans
  • Injections, Intravenous
  • Radioimmunoassay
  • Thyrotropin / blood
  • Thyrotropin-Releasing Hormone / blood
  • Thyrotropin-Releasing Hormone / pharmacokinetics*
  • Thyrotropin-Releasing Hormone / pharmacology*
  • Time Factors

Substances

  • Thyrotropin-Releasing Hormone
  • Thyrotropin